August 14, 2017 6:15pm
As Biostage (BSTG) fails to deliver on the adult Cellspan esophageal product, thus no IND will be filed as heralded for the last 2 years also …
No response to its filed dismissal of a terminal death suit … a telling reminder of its first failure and a potential death knell
ll that shareholder money down the drain and then forced to do yet another down financing ($0.315) as the architect (its CMO and president) of multiple failures is elevated to the BOD
The new lead program is strange to now go after pediatric esophageal atresia; there is an approved device by Cook Medical – another rope-a-dope?
Way to go BSTG, reward failure … as shareholders bear the brunt of megalomania and the stock closes down -$0.09 or -17.71%
Pre-open indications: 3 hit and 0 miss
It’s called premium content for a reason … I define insight from a real-time perspective discussing equity share pricing, attractiveness and support levels as stock pricing changes by the hour … if not the minute!
Others don’t even come close!
I answer one question, in which company should investors commit and keep their money.
Monday’s results have implications to Failureday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!
Henry’omics:
From the pre-open’s investor’s newsletter, “…geo-political tensions are easing; markets look hot at the open … After the rotations going into the weekend. Will today lift all boats in the sector?
As I had stated …
· The recent flip-flops of the cell therapy and regenerative medicine sector are typical of a tired market!
· Last week I pointed out that there were a number of Q2 results that made me nervous about some of the sector’s “run-ways”.
· This included the lagging action of many loss-per-share announcements as weak relative performance that will under power the sector and ... I also pointed out that the sector was just “one up day away from another down”.
· The advance/decline lines are bickering with fundamentals, technical and charts as negative seasonal bias continues to take its toll.
In reference to the title - Biostage (BSTG), it speaks for itself … RUN and RUN fast from this equity …!!
This is strange to now go after pediatric esophageal atresia … there is an approved device. FDA approval granted to pediatric device used to treat esophageal birth defect-May 25, 2017
Does …“the company also believes the pediatric esophageal atresia program needs to advance in the first position with the FDA to ensure eligibility for the pediatric voucher program that could potentially provide tens of millions of dollars of non-dilutive financing for additional development in other indications. <J Kolbert, Maxim>
One can't defraud the government without ... consequence ...!!!
The advance/decline line scenario of 43 SCGT & RT covered companies:
· The first hour was positive with an A/DL of 27/14 and 2 flats;
· The mid-day was positive with an A/DL of 27/13 and 3 flat;
· The close was positive with an A/DL of 28/12 and 3 flat;
Pre-open indications: 3 hit and 0 miss
- Biostage (BSTG) closed down -$0.09 – hit;
- BioLife Solutions (BLFS) closed up +$0.00 – hit;
- Capricor (CAPR) closed up +$0.10 – hit;
Regenerative Medicine Earnings Scorecard - Q2/2017 - to date … 30 out of 43 covered – so far
http://www.regmedinvestors.com/articles/9841
Daily analytics:
U.S. stocks gained on Monday with the S&P 500 rising 1% for the first time in three months as the verbal standoff between the U.S. and North Korea cooled for now.
The S&P 500 added 24.52 points, or 1%, to close at 2,465.84, the Dow rose 135.39 points, or 0.6%, to close at 21,993.71 while the Nasdaq advanced 83.68 points, or 1.3%, to finish at 6,340.23.
Monday’s gains restored the S&P and NASDAQ above their 50-day moving averages, in the latest example of investors using any decline as an opportunity to buy on the dip.
The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, trading at 12.38 and was down -20.18% …
- Friday traded at 15.51, down -3.20% following Thursday’s 16.04, a +44.37% increase, Wednesday traded at 11.19, up +2.10%, Tuesday traded at 11.03, up +11.08% and last Monday traded at 9.93 … down -1%
Welcome to another day of the sector’s roller coaster …
… The iShares Russell 2000 (IWM) indicated:
· Monday was up +1.49%
· Friday +0.15%
· Thursday -1.82%
· Wednesday -0.86%
· Tuesday -0.31%
· Last Monday +0.16%
… The iShares NASDAQ Biotechnology (IBB) indicated:
· Monday was up +1.03%
· Friday +0.64%
· Thursday -2.82%
· Wednesday -0.32%
· Tuesday -9,94%
· Last Monday +0.54%
The count - decliners versus gainers:
……. look at the differences in the spreads as decliners jump and %’s migrate…
· Monday’s decliners ranged from -0.24% <RGNX> to -17.71% <BSTG> in 12 equities;
· Friday’s decliners ranged from -0.46% <KITE> to -11.97% <IMUC> in 14 equities;
· Thursday’s decliners ranged from -0.31% <KITE> to -11.52% <VSTM> in 33 equities;
· Wednesday’s decliners ranged from -0.16% <OSIR> to -21.24% <BLCM> in 31 equities;
· Tuesday’s decliners ranged from -0.46% <BCLI> to -11.11% <CUR> in 28 equities;
· Last Monday’s decliners ranged from -0.21% <CLLS> to -16.07% <NWBO> in 17 equities;
Versus
… Look at the percentage’s (%) and spreads …
· Monday’s gainers ranged from +0.88% <ADRO> to +26% <IMUC> in 28 equities;
· Friday’s gainers ranged from +0.06% <BSTG> to +11.43% <CUR> in 28 equities;
· Thursday’s gainers ranged from +0.32% <OSIR> to +12.43% <SGMO> in 8 equities;
· Wednesday’s gainers ranged from +0.71% <KITE> to +13.33% <VCEL> in 10 equities;
· Tuesday’s gainers ranged from +0.19% <ONCE> to +5.79% <KITE> in 14 equities;
· Last Monday’s gainers ranged from +0.12% <IMUC> to +30.43% <BSTG> in 22 equities;
Some of MY working trend lines or indications:
… The greatest volume to the downside: BSTG, XON, NWBO, BLCM and JUNO
… Upside volume was weighted to: SGMO, IMUC, MDXG, CAPR and VCEL
… Biggest $ downside: XON, BLCM, JUNO, BSTG and MESO
… Largest $ upside: ONCE, KITE, BLUE, SGMO, MDXG and AXGN
… Flat: ADVM, BLFS and HSGX
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.